N-[5-(2,2-dimethylpropyl)-1,3,4-thiadiazol-2-yl]acetamide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-[5-(2,2-dimethylpropyl)-1,3,4-thiadiazol-2-yl]acetamide
• 化学式: C₉H₁₅N₃OS
• mdl: MFCD03616219
• 分子量: 213.3
• InChiKey: SXDWGUHFZHQPND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] PYRROLIDINE GLYCOSIDASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRROLIDINE GLYCOSIDASE
  申请人：ASCENEURON S A

  公开号：WO2020039027A1

  公开（公告）日：2020-02-27

  Compounds of formula (I) wherein A, W, R3b, Z and p have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

  式（I）中A、W、R3b、Z和p的含义如权利要求所述，可用于治疗tau病和阿尔茨海默病。
• Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US11530210B2

  公开（公告）日：2022-12-20

  Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

  取代的吡唑并吡啶作为 GluN2B 受体配体。此类化合物可用于调节 GluN2B 受体，以及用于治疗由 GluN2B 受体活性介导的疾病状态、紊乱和病症的药物组合物和方法。
• SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20210017169A1

  公开（公告）日：2021-01-21

  Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
• SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS
  申请人：Asceneuron SA

  公开号：US20210206766A1

  公开（公告）日：2021-07-08

  Compounds of formula (I), wherein A, R, L, Z, Q 1 , Q 2 and n have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
• PYRROLIDINE GLYCOSIDASE INHIBITORS
  申请人：Asceneuron SA

  公开号：US20210213005A1

  公开（公告）日：2021-07-15

  Compounds of formula (I), wherein A, W, R 3b , Z and p have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.